Powder: -20°C for 3 years | In solvent: -80°C for 1 year
HJC0350 是一种有效地、选择性的EPAC2拮抗剂(IC50:0.3 µM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 218 | 现货 | ||
5 mg | ¥ 497 | 现货 | ||
10 mg | ¥ 663 | 现货 | ||
25 mg | ¥ 1,390 | 现货 | ||
50 mg | ¥ 2,310 | 现货 | ||
100 mg | ¥ 3,950 | 现货 | ||
200 mg | ¥ 5,650 | 现货 | ||
500 mg | ¥ 8,680 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 493 | 现货 |
产品描述 | HJC0350 is an effective and specific EPAC2 inhibitor (IC50: 0.3 μM), and no inhibition of Epac1. |
靶点活性 | EPAC2:0.3 μM |
体外活性 | HJC0350 selectively blocks cAMP-induced EPAC2 activation but do not inhibit cAMP-mediated PKA activation. In HEK293/EPAC2-FL cells, HJC0350 also inhibits 007-AM mediated cellular activation of EPAC2. [1] |
激酶实验 | In Vitro IRE1 RNase and RIDD Assays: Analysis of radiolabeled Xbp1 substrate cleavage is performed as previously except that mammalian IRE1 reaction buffer is used. In vitro RIDD substrates are synthesized by in vitro transcription using the T7-MAXIscript Kit in the presence of 32P ATP or Cy5-UTP on templates isolated by RT-PCR from mouse Min6 cells (Ins2) or PCR from cloned XBP1 cDNA. The resulting products are gel purified to obtain full-length substrate. Reactions are then separated by 15% UREA-PAGE for analysis by phosphorimaging or by near-infrared imaging using the LI-COR Odyssey scanner. |
分子量 | 277.38 |
分子式 | C15H19NO2S |
CAS No. | 885434-70-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 13.9 mg/mL (50 mM)
Ethanol: 5.6 mg/mL (20 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 3.6052 mL | 18.0258 mL | 36.0516 mL | 90.1291 mL |
5 mM | 0.721 mL | 3.6052 mL | 7.2103 mL | 18.0258 mL | |
10 mM | 0.3605 mL | 1.8026 mL | 3.6052 mL | 9.0129 mL | |
20 mM | 0.1803 mL | 0.9013 mL | 1.8026 mL | 4.5065 mL | |
DMSO | 50 mM | 0.0721 mL | 0.3605 mL | 0.721 mL | 1.8026 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
HJC0350 885434-70-8 GPCR/G Protein cAMP inhibit Inhibitor HJC-0350 HJC 0350 inhibitor